SFGP
NVCR icon

Stonebridge Financial Group (Pennsylvania)’s NovoCure NVCR Stock Holding History

Stonebridge Financial Group (Pennsylvania)’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-300
Closed -$5.35K – 691
2025
Q1 		$5.35K Hold
300
– – ﹤0.01% 694
2024
Q4 		$8.94K Buy
+300
New +$6.35K ﹤0.01% 608

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Stonebridge Financial Group (Pennsylvania)'s NVCR Position: Q2 2025 in Review

Stonebridge Financial Group (Pennsylvania) sold out of NovoCure (NVCR) in Q2 2025, closing a stake of 300 shares — an estimated $5.35K sold.

Stonebridge Financial Group (Pennsylvania) first reported a position in NVCR in Q4 2024 and held it in 2 quarters. The position peaked at $8.94K in Q4 2024. 242 funds tracked by Wall St. Rank hold NVCR as of Q2 2025.

  • Stonebridge Financial Group (Pennsylvania) reported no remaining NovoCure position as of Q2 2025 after selling out during the quarter.
  • Stonebridge Financial Group (Pennsylvania) sold 300 NovoCure shares in Q2 2025, an estimated $5.35K.
  • Stonebridge Financial Group (Pennsylvania) first reported a position in NovoCure in Q4 2024 and held it in 2 quarters.
  • Stonebridge Financial Group (Pennsylvania)'s NovoCure position peaked at $8.94K in Q4 2024.
  • 242 funds tracked by Wall St. Rank held NovoCure as of Q2 2025.

Based on Stonebridge Financial Group (Pennsylvania)'s 13F filing for Q2 2025, filed 24 Jul 2025.